A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells

Naohiko Shimada, Cevayir Coban, Yoichi Takeda, Masami Mizu, Jusaku Minari, Takahisa Anada, Yuichi Torii, Seiji Shinkai, Shizuo Akira, Ken J. Ishii, Kazuo Sakurai

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Oligodeoxynucleotides containing unmethylated CpG sequences (CpG DNAs) activate the vertebrate innate immune system via toll-like receptor 9 (TLR-9). Although CpG DNA is a promising immunotherapeutic agent, its short circulation time in biological fluids due to nuclease is the major drawback. This paper proposes that a natural polysaccharide called schizophyllan (SPG) can be used as an effective CpG DNA carrier because SPG can complex with CpG DNA and the resultant complex shows the nuclease resistance of the bound DNA. In order to increase cellular uptake in vitro, we chemically attached spermine, cholesterol, arginine octamer, or RGD peptide to SPG. The complexes made of the chemically modified SPG and CpG DNA having a phosphorothioate (PS) or phosphodiester (PO) backbone led to increased secretion of cytokines of about 4- to 15-fold, compared with the uncomplexed dose. Furthermore, when PO CpG DNA was complexed with unmodified SPG, the IL-12 level increased by almost 3- to 11-fold compared with the naked dose. The PO CpG DNA/unmodified SPG complex data suggested that unmodified SPG might effectively deliver PO in vivo due to the electrically neutral nature of unmodified SPG. When the complexed CpG DNAs were injected intraperitoneally, a large amount of IL-12 production was observed compared with the uncomplexed material. Both in vivo and vitro assays indicated that the SPG complex may be of use for CpG DNA therapy.

Original languageEnglish
Pages (from-to)1280-1286
Number of pages7
JournalBioconjugate Chemistry
Volume18
Issue number4
DOIs
Publication statusPublished - Jul 1 2007

Fingerprint

Antigen-Presenting Cells
Polysaccharides
DNA
Interleukin-12
Sizofiran
Toll-Like Receptor 9
Spermine
Oligodeoxyribonucleotides
Arginine
Immune system
DNA sequences
Cholesterol
Genetic Therapy
Vertebrates
Immune System
Peptides
Assays
Cytokines
Fluids

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells. / Shimada, Naohiko; Coban, Cevayir; Takeda, Yoichi; Mizu, Masami; Minari, Jusaku; Anada, Takahisa; Torii, Yuichi; Shinkai, Seiji; Akira, Shizuo; Ishii, Ken J.; Sakurai, Kazuo.

In: Bioconjugate Chemistry, Vol. 18, No. 4, 01.07.2007, p. 1280-1286.

Research output: Contribution to journalArticle

Shimada, N, Coban, C, Takeda, Y, Mizu, M, Minari, J, Anada, T, Torii, Y, Shinkai, S, Akira, S, Ishii, KJ & Sakurai, K 2007, 'A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells', Bioconjugate Chemistry, vol. 18, no. 4, pp. 1280-1286. https://doi.org/10.1021/bc0700178
Shimada, Naohiko ; Coban, Cevayir ; Takeda, Yoichi ; Mizu, Masami ; Minari, Jusaku ; Anada, Takahisa ; Torii, Yuichi ; Shinkai, Seiji ; Akira, Shizuo ; Ishii, Ken J. ; Sakurai, Kazuo. / A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells. In: Bioconjugate Chemistry. 2007 ; Vol. 18, No. 4. pp. 1280-1286.
@article{7c1b3b80be0e47f19be86cdde8488a4d,
title = "A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells",
abstract = "Oligodeoxynucleotides containing unmethylated CpG sequences (CpG DNAs) activate the vertebrate innate immune system via toll-like receptor 9 (TLR-9). Although CpG DNA is a promising immunotherapeutic agent, its short circulation time in biological fluids due to nuclease is the major drawback. This paper proposes that a natural polysaccharide called schizophyllan (SPG) can be used as an effective CpG DNA carrier because SPG can complex with CpG DNA and the resultant complex shows the nuclease resistance of the bound DNA. In order to increase cellular uptake in vitro, we chemically attached spermine, cholesterol, arginine octamer, or RGD peptide to SPG. The complexes made of the chemically modified SPG and CpG DNA having a phosphorothioate (PS) or phosphodiester (PO) backbone led to increased secretion of cytokines of about 4- to 15-fold, compared with the uncomplexed dose. Furthermore, when PO CpG DNA was complexed with unmodified SPG, the IL-12 level increased by almost 3- to 11-fold compared with the naked dose. The PO CpG DNA/unmodified SPG complex data suggested that unmodified SPG might effectively deliver PO in vivo due to the electrically neutral nature of unmodified SPG. When the complexed CpG DNAs were injected intraperitoneally, a large amount of IL-12 production was observed compared with the uncomplexed material. Both in vivo and vitro assays indicated that the SPG complex may be of use for CpG DNA therapy.",
author = "Naohiko Shimada and Cevayir Coban and Yoichi Takeda and Masami Mizu and Jusaku Minari and Takahisa Anada and Yuichi Torii and Seiji Shinkai and Shizuo Akira and Ishii, {Ken J.} and Kazuo Sakurai",
year = "2007",
month = "7",
day = "1",
doi = "10.1021/bc0700178",
language = "English",
volume = "18",
pages = "1280--1286",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells

AU - Shimada, Naohiko

AU - Coban, Cevayir

AU - Takeda, Yoichi

AU - Mizu, Masami

AU - Minari, Jusaku

AU - Anada, Takahisa

AU - Torii, Yuichi

AU - Shinkai, Seiji

AU - Akira, Shizuo

AU - Ishii, Ken J.

AU - Sakurai, Kazuo

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Oligodeoxynucleotides containing unmethylated CpG sequences (CpG DNAs) activate the vertebrate innate immune system via toll-like receptor 9 (TLR-9). Although CpG DNA is a promising immunotherapeutic agent, its short circulation time in biological fluids due to nuclease is the major drawback. This paper proposes that a natural polysaccharide called schizophyllan (SPG) can be used as an effective CpG DNA carrier because SPG can complex with CpG DNA and the resultant complex shows the nuclease resistance of the bound DNA. In order to increase cellular uptake in vitro, we chemically attached spermine, cholesterol, arginine octamer, or RGD peptide to SPG. The complexes made of the chemically modified SPG and CpG DNA having a phosphorothioate (PS) or phosphodiester (PO) backbone led to increased secretion of cytokines of about 4- to 15-fold, compared with the uncomplexed dose. Furthermore, when PO CpG DNA was complexed with unmodified SPG, the IL-12 level increased by almost 3- to 11-fold compared with the naked dose. The PO CpG DNA/unmodified SPG complex data suggested that unmodified SPG might effectively deliver PO in vivo due to the electrically neutral nature of unmodified SPG. When the complexed CpG DNAs were injected intraperitoneally, a large amount of IL-12 production was observed compared with the uncomplexed material. Both in vivo and vitro assays indicated that the SPG complex may be of use for CpG DNA therapy.

AB - Oligodeoxynucleotides containing unmethylated CpG sequences (CpG DNAs) activate the vertebrate innate immune system via toll-like receptor 9 (TLR-9). Although CpG DNA is a promising immunotherapeutic agent, its short circulation time in biological fluids due to nuclease is the major drawback. This paper proposes that a natural polysaccharide called schizophyllan (SPG) can be used as an effective CpG DNA carrier because SPG can complex with CpG DNA and the resultant complex shows the nuclease resistance of the bound DNA. In order to increase cellular uptake in vitro, we chemically attached spermine, cholesterol, arginine octamer, or RGD peptide to SPG. The complexes made of the chemically modified SPG and CpG DNA having a phosphorothioate (PS) or phosphodiester (PO) backbone led to increased secretion of cytokines of about 4- to 15-fold, compared with the uncomplexed dose. Furthermore, when PO CpG DNA was complexed with unmodified SPG, the IL-12 level increased by almost 3- to 11-fold compared with the naked dose. The PO CpG DNA/unmodified SPG complex data suggested that unmodified SPG might effectively deliver PO in vivo due to the electrically neutral nature of unmodified SPG. When the complexed CpG DNAs were injected intraperitoneally, a large amount of IL-12 production was observed compared with the uncomplexed material. Both in vivo and vitro assays indicated that the SPG complex may be of use for CpG DNA therapy.

UR - http://www.scopus.com/inward/record.url?scp=34547182835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547182835&partnerID=8YFLogxK

U2 - 10.1021/bc0700178

DO - 10.1021/bc0700178

M3 - Article

C2 - 17530815

AN - SCOPUS:34547182835

VL - 18

SP - 1280

EP - 1286

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 4

ER -